 This study found that the Armokran variant of SARS-CoV-2 was associated with lower risk of hospitalization, intensive care unit admission, oxygen therapy, and non-invasive or invasive ventilation than the Delta variant. Additionally, there was no difference in the risk of hospitalization between two sub-lineages of Armokran, BA.1 and BA.2. This suggests that the Armokran variant may be less severe than the Delta variant, but it also indicates that the two sub-lineages are equally effective at reducing the severity of illness. This article was authored by Lisa Arsky, Maria Divan Karkov, Janet Diaz, and others.